Simplified HCV Integrated Management Model in Methadone Clinics in Ukraine (SHIM)
The goal of this pragmatic, quasi-experimental cluster trial is to evaluate whether simplified, onsite hepatitis C virus (HCV) treatment integrated into opioid agonist maintenance therapy (OAMT) clinics improves cure rates compared with referral-based care in Ukraine . The study includes adults (18 years and older) receiving OAMT with confirmed chronic HCV infection and no prior HCV treatment.
The main questions it aims to answer are:
- Does onsite Simplified HCV Integrated Management (SHIM) increase the proportion of patients achieving sustained virologic response 12 weeks after treatment completion (SVR12) compared with case management and referral (CMR) to specialist clinics?
- Does adding provider pay-for-performance (P4P) incentives to SHIM further improve progression along the HCV treatment cascade and SVR12 rates?
Researchers compared three models of care across 13 OAMT clinics in 12 Ukrainian cities:
- Case Management and Referral (CMR): structured referral to off-site specialist clinics for HCV treatment
- SHIM: simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
- SHIM + P4P: SHIM with provider incentives linked to completion of key cascade milestones All SHIM clinics were supported by Project ECHO telementoring to strengthen clinician capacity . The study used nationally procured direct-acting antivirals (DAAs) under routine program conditions and did not reimburse diagnostic costs.
Between February 2023 and December 2024, 616 eligible patients were enrolled .
Participants:
- Completed confirmatory HCV RNA testing
- Underwent simplified pretreatment clinical and laboratory assessment
- Received 12 weeks of pan-genotypic DAA treatment either onsite (SHIM arms) or at specialist clinics (CMR arm)
- Attended follow-up visits during treatment for adherence assessment and counseling
- Were prescribed HCV RNA testing 12 weeks after treatment completion to confirm cure (SVR12) The primary outcome was SVR12. Secondary outcomes included completion of pretreatment evaluation, treatment initiation, treatment completion, and completion of SVR assessment.
This study evaluates HCV care under real-world conditions during ongoing national treatment scale-up in Ukraine. The findings inform whether integrating simplified HCV treatment into OAMT clinics-and aligning provider incentives-can improve cure rates and accelerate progress toward HCV elimination in high-burden populations.
調査の概要
状態
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Kyiv、ウクライナ、01054
- Ukrainian Institute on Public Health Policy
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- currently receiving treatment at the selected OAT site (implying a diagnosis of opioid dependence according to ICD 10);
- aged 18 years or older;
- residing within the study catchment area; and
- having a positive HCV antibody test documented in the medical chart
Exclusion Criteria:
- previous HCV treatment history;
- active tuberculosis (assessed using 4-item screening questionnaire and confirmed according to the current national protocol);
- pregnant or planning pregnancy in the next 6 months;
- planning to move to another city in the next 6 months;
- unwillingness to undergo confirmatory HCV RNA PCR test at their own expense and treat HCV
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Case Management and Referral
structured referral to off-site specialist clinics for HCV treatment
|
structured referral to off-site specialist clinics for HCV treatment
|
|
実験的:Simplified HCV Integrated Management
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
|
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
|
|
実験的:Simplified HCV Integrated Management + Pay-for-performance
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians with provider incentives linked to completion of key cascade milestones
|
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
provider incentives linked to completion of key cascade milestones
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Sustained virologic response
時間枠:Up to 24 weeks after treatment completion
|
Number of participants who have HCV RNA below the limit of quantitation (≤50 IU/mL) based on clinical records
|
Up to 24 weeks after treatment completion
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Completion of all pretreatment diagnostic assessments
時間枠:Through study completion, an average of 2 weeks after baseline
|
Number of participants who complete all pretreatment diagnostic assessments according to the SHIM algorithm (complete blood count, basic metabolic panel (including creatinine), hepatic function panel, fibrosis assessment, and HBsAg testing) based on clinical records
|
Through study completion, an average of 2 weeks after baseline
|
|
Treatment initiation
時間枠:Through study completion, an average of 4 weeks after baseline
|
Number of participants who are prescribed treatment for HCV infection based on clinical records
|
Through study completion, an average of 4 weeks after baseline
|
|
Treatment completion
時間枠:Through study completion, an average of 14 weeks after baseline
|
Number of participants who complete the full course of HCV treatment as prescribed based on clinical records
|
Through study completion, an average of 14 weeks after baseline
|
|
SVR assessment completion
時間枠:Up to 24 weeks after treatment completion
|
Number of participants who complete HCV RNA testing for SVR confirmation based on clinical records
|
Up to 24 weeks after treatment completion
|
|
HCV reinfection
時間枠:12 months after treatment completion
|
Number of participants who receive a positive result of HCV RNA test at 12 months after treatment completion, based on clinical records
|
12 months after treatment completion
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 127-2022
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD 共有時間枠
IPD 共有アクセス基準
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ICF
試験データ・資料
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
オピオイド使用障害の臨床試験
Case Management and Referralの臨床試験
-
Washington State UniversityNational Institute on Drug Abuse (NIDA)完了